Format

Send to

Choose Destination
Br J Psychiatry. 1998 Jul;173:54-60.

Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation.

Author information

1
Summit Research Network, Seattle, Washington 98104, USA.

Abstract

BACKGROUND:

This study compared the efficacy and safety of sertraline to placebo in treating panic disorder.

METHOD:

178 out-patients with panic disorder who exhibited at least four panic attacks during the four weeks prior to screening and three during the two weeks of lead-in were randomly assigned to 12 weeks of double-blind treatment with sertraline (50, 100 or 200 mg) or placebo.

RESULTS:

Sertraline was superior to placebo in reducing the number of panic attacks, situational attacks, unexpected attacks, limited symptom attacks, and time spent worrying (all P < 0.01) and the Hamilton Anxiety Scale (P < 0.05), although Clinical Global Impression (Improvement) did not significantly differentiate groups at 12 weeks and at end-point. No serious adverse events were associated with sertraline. No dose relationship was found for adverse events; overall drop-out rates were not different for sertraline or placebo, although more sertraline-treated subjects discontinued for adverse events, typically early in the study. Only dry mouth and ejaculation failure (primarily ejaculation delay) were associated significantly with sertraline.

CONCLUSIONS:

Sertraline was effective and safe in reducing panic attacks. Higher doses were no more effective than the 50 mg dose.

PMID:
9850204
DOI:
10.1192/bjp.173.1.54
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Cambridge University Press
Loading ...
Support Center